About Oncology Biosimilars
Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting. Biosimilars are synthesized with the use of biologic components such as monoclonal antibodies, proteins, hormones, nucleic acids, colony stimulating factors, interleukins, and enzymes.
Technavio’s analysts forecast the global oncology biosimilars market to grow at a CAGR of 31.76% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global oncology biosimilars market for the period 2016-2020. To calculate the market size, the report considers revenue generated from the sales of biosimilars used to treat cancer.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Oncology Biosimilars Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Oncology Biosimilars Market: Biocon, Celltrion, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, Hospira, Mylan and Sandoz.
Other Prominent Vendors in the market are: AbbVie, Allergan, Amgen, AstraZeneca, Baxter, Biogen, BioXpress Therapeutics, Boehringer Ingelheim, Cipla, Coherus BioSciences, Coherus BioSciences, Daiichi Sankyo, Emcure Pharmaceuticals, GlaxoSmithKline (GSK), Intas Pharmaceuticals, Merck, Pfizer, Sanofi, 3SBio and Wockhardt.
Commenting on the report, an analyst from Technavio’s team said: “It is expected that the trend of outsourcing drug manufacturing to developing countries to have a significant impact on the market. Outsourcing the production of biosimilars reduced the overall cost of manufacturing biosimilars, making them affordable.”
According to the report, a number of biological patents are either about to expire during the forecast period or have already expired. The patent expiries of branded drugs results in the entry of less expensive biosimilars, boosting the market growth.
Further, the report states that the risk related to the failure of the drugs and the high investment needed during the developmental stage hampers the growth of the market.
Biocon, Celltrion, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, Hospira, Mylan, Sandoz, AbbVie, Allergan, Amgen, AstraZeneca, Baxter, Biogen, BioXpress Therapeutics, Boehringer Ingelheim, Cipla, Coherus BioSciences, Coherus BioSciences, Daiichi Sankyo, Emcure Pharmaceuticals, GlaxoSmithKline (GSK), Intas Pharmaceuticals, Merck, Pfizer, Sanofi, 3SBio ,Wockhardt.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook